Sugi Predict

Sugi Predict / Compounds / SCHEMBL722886

SCHEMBL722886

SCHEMBL722886

CN(C)c1ccc(-c2nc(C(=O)c3ccc(F)cc3)c[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TCF4 P15884 1/20 0.46
▸ CTNNB1 P35222 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ HPGD P15428 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ CNR2 P34972 1/20 0.44
▸ ALOX5 P09917 1/20 0.43
▸ ESR1 P03372 1/20 0.42
▸ APP P05067 3/20 0.42
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ SNCA P37840 1/20 0.40
▸ BRCA1 P38398 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724434 0.85 ALDH1A1 (0.42) HPGDALDH1A1ESR1NPC1RAB9A
Hydrochloric Acid SCHEMBL724182 0.84 ALDH1A1 (0.41) HPGDALDH1A1ALOX5ESR1NPC1
SCHEMBL723473 0.83 CHEK2 (0.41) ALDH1A1CNR2NPC1KMT2AMEN1
SCHEMBL724793 0.82 HTT (0.41) MAPTHPGDALDH1A1NPC1RAB9A
SCHEMBL723344 0.82 MAPT (0.47) MAPTHPGDALDH1A1ALOX5NPC1
SCHEMBL725555 0.77 ALDH1A1 (0.49) MAPTALDH1A1HDAC1HDAC6LMNA
SCHEMBL771455 0.77 AAK1 (0.53) MAPTALDH1A1NPC1RAB9AKMT2A
SCHEMBL9292264 0.75 MAPT (0.79) MAPTHPGDALDH1A1ESR1APP
SCHEMBL27601952 0.74 NR4A2 (0.46) ALDH1A1ALOX5KMT2AMEN1KDM4E
SCHEMBL725004 0.74 TUBB4A (0.47) MAPTALDH1A1TP53KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
CN-117396505-A Methods of treating inflammation 维鲁公司 2024-01-12 — — CN disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 — — US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 — — US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 — — WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 TCF4 1543/4885CTNNB1 1448/4885MAPT 2614/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TCF4 1543/4885CTNNB1 1448/4885MAPT 2614/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 TCF4 4341/4885CTNNB1 1582/4885MAPT 36/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TCF4 1543/4885CTNNB1 1448/4885MAPT 2614/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB TCF4 4101/4885CTNNB1 2779/4885MAPT 45/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TCF4 1543/4885CTNNB1 1448/4885MAPT 2614/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 TCF4 1543/4885CTNNB1 1448/4885MAPT 2614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.